ASND thrives amid market volatility, with Yorvipath's strong potential & strategic focus on rare diseases. Click here to find ...

The implications for Eli Lilly and Novo Nordisk seem pretty clear: The immediate removal of a rival for the massive revenues ...

Denmark’s economy was reshaped by Novo Nordisk and obesity drugs. That identity is now under attack on multiple fronts, from ...

In US dollar terms that equated to around $25.5bn, which was slightly towards the higher end of guidance of between $25bn and ...

An ex-manager for Novo Nordisk Inc. reached a settlement in her lawsuit alleging the healthcare company failed to accommodate her disabilities, retaliated against her, and wrongfully terminated her.

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire ...

Novo Nordisk , the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil ...

A rapidly escalating trade war has socked stocks as investors weigh the fallout from President Trump’s tariff barrage.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Novo Nordisk's head of commercial strategy and corporate affairs, Camilla Sylvest, has decided to leave the company, the ...

Novo Holdings, the controlling shareholder of Ozempic-maker Novo Nordisk (NVO), nearly doubled its annual income and ...

(Bloomberg) -- As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued at more than $600 billion are becoming a distant memory.